FRA:GU5's ROA % is ranked better than 65.83% of 120
companies
in the Medical Distribution industry
Industry Median: 2.23
vs FRA:GU5: 3.51
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Guangzhou Baiyunshan Pharmaceutical Holdings Co ROA % Related Terms
Guangzhou Baiyunshan Pharmaceutical Holdings Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co ROA % Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co ROA % vs Medical Distribution Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a ROA % of 8.33% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. This is 45% above median its historical median of 5.74. Over the past decade, Guangzhou Baiyunshan Pharmaceutical Holdings Co's ROA % has ranged from 3.51 to 8.56. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #41 out of 120 companies in the Medical Distribution industry, placing it in the top 34.2%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's ROA % too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current ROA % of 8.33% is 45% above median its 10-year median of 5.74. Over the past 10 years, this metric has ranged from a low of 3.51 to a high of 8.56. The Medical Distribution industry median ROA % is 2.23. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 8.33% is 273.5% above this industry median. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #41 out of 120 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's ROA % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #41 out of 120 companies for ROA %. This puts Guangzhou Baiyunshan Pharmaceutical Holdings Co in the upper half of its industry. The industry median ROA % is 2.23. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 8.33% is 273.5% above this benchmark. Historically, Guangzhou Baiyunshan Pharmaceutical Holdings Co's own ROA % has ranged from 3.51 to 8.56 over the past decade. While the company's 10-year median is 5.74 vs. the industry median of 2.23, Guangzhou Baiyunshan Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.23, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current ROA % of 8.33% is 273.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. For the Medical Distribution industry, the median ROA % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current ROA % is 8.33%, which is 45% above median its own 10-year median of 5.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.30, compared to a current price of €1.55 — trading 32.6% below its estimated fair value. The current ROA % is 8.33%, which is 45% above median its 10-year median of 5.74 and 273.5% above the Medical Distribution industry median of 2.23. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current ROA % is 8.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.55 is trading 32.6% below its estimated GF Value™ of €2.30.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.
Key valuation signals for FRA:GU5:
ROA %: 8.33% (45% above median its 10-year median of 5.74)
GF Value™: €2.30 vs. price of €1.55 (32.6% below fair value)
Industry Position: 273.5% above the Medical Distribution median (#41 of 120)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
68GF Score
Get the complete analysis for FRA:GU5
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
